Reuters broke the news that European private equity firm Ardian has clinched a deal to buy Italian drug firm Biofarma Group for about 1.1 billion euros ($1.26 billion) — its second pharmaceutical deal in less than a year. The transaction will see Ardian expanding in the lucrative dietary supplement market, an industry that has been booming during the COVID-19 pandemic as people have turned to multivitamin products to boost their immunity.
DealsHealth
Reuters reveals Buyout fund Ardian makes $1.2 bln swoop on Italy’s Biofarma Group
16 January 2022, 10:02 am. 1 minute
Article Tags
Topics of Interest: DealsHealth
Type: Reuters Best
Sectors: Business & FinancePharmaceuticals & Healthcare
Regions: Europe
Win Types: Speed
Media Types: Text
Customer Impact: Important Regional Story
More of Reuters Best
Reuters exclusively reports Indian sugar mills to close early as rain hits cane supply; sugar futures jump; shares fall
January 29, 2023
Reuters reveals that India may peg gross borrowing under 16 trillion rupees in 2023/24
January 27, 2023